R&D na Sorrento yana mai da hankali kan haɓaka sabbin abubuwa a cikin COVID-19, maganin cutar kansa, cikakken kula da ciwo da cututtukan autoimmune.

Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
Shirye-shiryen COVID-19
COVISTIX (diagnostic) Gwajin Antigen gaggawa 0%* Izinin Amfani da Gaggawa (EUA) a Mexico (COFEPRIS), Brazil (ANVISA), da CE Alama a Turai COVIMARK™ (diagnostic) Gwajin Antigen gaggawa 0%* Aikace-aikacen da aka ƙaddamar a cikin Amurka da Kanada don Izinin Amfani da Gaggawa (EUA) COVISHIELD™ (maganin magani) Neutralizing Antibody (IN) a cikin marasa lafiya da marasa lafiya 40%* COVISHIELD™ (maganin magani) Neutralizing Antibody (IV) a cikin marasa lafiya da marasa lafiya 20%* FUJOVEE (Abivertinib) Mummunan COVID-19 a cikin Marasa lafiya na ICU 82%* Muhimmin Gwajin da ke jiran Cirewar FDA OQORY™ (COVI-MSC) ARDS saboda COVID-19 a cikin marasa lafiya na ICU 82%* Muhimmin gwaji a Brazil Mpro Mai hanawa (kwayoyin baka) Anti rigakafi 40%* Omicron mRNA rigakafin maganin 20%*
Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
immunotherapy
FUJOVEE (Abivertinib) Bayanin NSCLC 82%* FUJOVEE (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE (Abivertinib) prostate 20%* FUJOVEE (Abivertinib) Lupus 20%* FUJOVEE (Abivertinib) MS 20%* FUJOVEE (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* *A cikin haɗin gwiwa tare da Lee's Pharm a China PD-L1 (STI-3031)** Cercical Cancer 82%* ** A Amurka kuma tare da haɗin gwiwar ImmuneOncia a Koriya CD47 Tumburai masu ƙarfi 40%* CD38 DAR-T Multiye Myeloma 40%* Saukewa: CD38D Amyloidosis, Multiple Myeloma, T-ALL, da esophageal 40%* TROP2 ADC* Tumburai masu ƙarfi 40%* * A kasar Sin Seprehvec™ oncolytic cutar Ciwon Ciwon Ciki; Ciwon daji na CNS 40%* Farashin BCMA Tuwon Ruwa 20%* Bevacizumab-ADNAB™ Ciwon daji na Endometrial 40%* A haɗin gwiwa tare da Mayo Clinic Bevacizumab-ADNAB™ Ovarian Ciwon daji 40%* A haɗin gwiwa tare da Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* A haɗin gwiwa tare da Mayo Clinic
Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
Pain
ZTlido™ 1.8% Postherpetic Neuralgia - PHN 99.8%* SP-102 (SEMDEXA) Lumbar Radicular / Sciatica Pain 82%* SP-103 (Tsarin Topical Lidocaine 5.4%) Ciwon Baya 20%* SP-104 (An jinkirta fashe Low Dose Naltrexone) Fibromyalgia 20%* RTX (resiferatoxin) Epidural allura Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Kankara 60.3%* Sunan marayu RTX (resiferatoxin) Hanyar intra-articular Matsakaici zuwa Ƙunƙarar Ƙifin OA 60.2%*
Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
Bayarwa Lymphatic
Sofusa® anti-TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL) 40%* Sofusa® anti-CTLA-4 Melanoma 40%* A haɗin gwiwa tare da Mayo Clinic

Shirye-shiryen COVID-19
Mabuɗin Shirye-shirye (Alamar)	Phase
COVISTIX (diagnostic) FDA EU COVIMARK™ (diagnostic) FDA EU COVISHIELD™ (maganin magani) PH I COVISHIELD™ (maganin magani) Preclinical FUJOVEE (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Mpro Inhibitor (kwayoyin baka) (anti-viral) Ph I Omicron mRNA rigakafin (alurar rigakafi) Preclinical

immunotherapy
Mabuɗin Shirye-shirye (Alamar)	Phase
FUJOVEE™ (Abivertinib) (NSCLC) Ph III FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II FUJOVEE™ (Abivertinib) (Prostate) Preclinical FUJOVEE™ (Abivertinib) (Lupus) Preclinical FUJOVEE™ (Abivertinib) (MS) Preclinical FUJOVEE™ (Abivertinib) (GvHD) Preclinical PD-L1 (Socazolimab)*(SCLC) Ph III PD-L1 (STI-3031)** (Cancer mahaifa) Ph III CD47 (Tsarin Tumor) Ph I CD38 DAR-T (Multiple Myeloma) Ph I Saukewa: CD38D (Amyloidosis, Multiple Myeloma, T-ALL, da esophageal) Ph I TROP2 ADC* (Tsarin Tumor) Ph I Seprehvec™ oncolytic cutar (Tsarin Ciwon Ciwon Ciki; Ciwon Ciwon Ciki) PH I Farashin BCMA (Magungunan Liquid) Preclinical Bevacizumab-ADNAB™ (Cancer Endometrial) Ph I Bevacizumab-ADNAB™ (Cancer Ovarian) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I

Pain
Mabuɗin Shirye-shirye (Alamar)	Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval SP-102 (SEMDEXA) Ph III SP-103 (Tsarin Topical Lidocaine 5.4%) Preclinical SP-104 (An jinkirta fashe Low Dose Naltrexone) Preclinical RTX (resiniferatoxin) allurar epidural (Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciki) Ph II RTX (resiniferatoxin) Hanya ta ciki (Matsakaici zuwa Ciwon Knee mai tsanani na OA) Ph II

Bayarwa Lymphatic
Mabuɗin Shirye-shirye (Alamar)	Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I